VialOwlLibrary / Growth hormone
Mod GRF 1-29
Also known as CJC-1295 without DAC, Modified GRF (1-29), Tetrasubstituted GRF 1-29
Largely unstudied
Modified version of the first 29 amino acids of growth hormone releasing hormone, altered to resist breakdown. Very little published research on this specific modified form in humans.
Not an approved medicine. Mod GRF 1-29 is not an approved medicine for this use in Australia or the United States. This page summarises published research for information only. It is not a recommendation to use Mod GRF 1-29, and VialOwl does not sell or supply it.
Background
Mod GRF 1-29 is the first 29 amino acids of human growth hormone releasing hormone with four amino acids swapped to slow its breakdown. The swaps came out of 1980s and 1990s drug company research into GRF analogues that resist the enzyme DPP-4. The street name CJC-1295 without DAC borrows from ConjuChem's CJC-1295, which had an added drug affinity complex (DAC) to make it last for days.
How it is thought to work
It acts like the body's own growth hormone releasing hormone, prompting the pituitary to release a pulse of growth hormone, which in turn raises IGF-1. Without the DAC it is still expected to be short acting.
What is claimed, and the evidence
| Claim | Evidence | Notes |
|---|---|---|
| Raises growth hormone and IGF-1 | Small human studies | Shown in small trials of the related long acting CJC-1295 with DAC and of native GRF; no published human trials of this exact tetrasubstituted form were found. |
| Muscle gain, fat loss, better sleep and recovery | No published evidence | Marketed and forum claims; no human outcome trials. |
| Anti ageing | No published evidence | No supporting human evidence. |
Side effects
| Effect | How often | Notes |
|---|---|---|
| Increased heart rate and flushing (systemic vasodilatory reaction) Serious | Frequency unknown | FDA identified these serious adverse events with CJC-1295; not studied for Mod GRF 1-29 specifically. |
| Injection site reactions | Frequency unknown | Reported for GH axis peptides in general in a 2026 clinical review. |
| Fluid retention, joint and muscle aches, blood sugar changes | Frequency unknown | Described in a 2026 review as typical of peptides raising growth hormone and IGF-1; no specific data for this compound. |
| Immune reactions to the product Serious | Frequency unknown | FDA flagged immunogenicity and peptide impurity risks for compounded CJC-1295. |
Warnings
- Almost no published human research exists on this specific modified peptide; evidence is borrowed from related compounds.
- Schedule 4 in Australia under the growth hormone releasing hormone class entry; not on the ARTG.
- Unapproved products are not assessed by the TGA for quality, safety or efficacy and may be contaminated, non-sterile, underdosed, overdosed or contain a different substance altogether.
Regulatory status
- Australia
- Not included on the ARTG (unapproved). Schedule 4 in the Poisons Standard under the class entry for growth hormone releasing hormones, with Appendix D clause 5 possession controls.
- United States
- Not FDA approved. No specific FDA compounding category entry found.
Sources
- PubMed: Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs
- PubMed: Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
- PubMed: The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (updated 22 April 2026)
- Poisons Standard June 2026 (Federal Register of Legislation)
Also in Growth hormone
From the VialOwl library, reviewed 26 September 2026. For education and general information. It is not medical advice and not a recommendation to use Mod GRF 1-29.